Agent Directed Therapeutic (ADTX) FY25 OTA

July 26, 2024 0

Anticipated Release Date: Q1FY25 New start OTA award for ADTX Responding to this opportunity requires membership in the Countering Weapons of Mass Destruction Consortium. This Consortium releases numerous solicitations throughout the year, so even if this Read More

Accelerated Antibodies Modification

July 23, 2024 0

Anticipated Release Date: Q3FY24: Modification of existing Accelerated Antibodies agreement for additional monoclonal antibody prototype. Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even Read More

Diagnostic Platforms for Agnostictoxin Detections

July 23, 2024 0

Anticipated Release Date: Q2FY25 Develop diagnostic and detection assays, platforms, or devices to sense exposures of emerging toxins, to include naturally occurring (e.g. marine, fungal, snake venom, small molecules) or synthetically-derived threats. Responding to this opportunity Read More

Vaccines Capability Area

April 19, 2024 0

Anticipated Release Date: Q3FY24 OR Q4FY24 Multiple Topics TBD—Possible 3 or 4 The goal of the Vaccines Capability Area is to conduct research in order to develop lead candidate vaccines and pretreatments that can be administered Read More

1 2 3